Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors

Recruiting now · Phase 4

Conditions studied: Coronary Artery Disease

In brief

Ticagrelor currently represents the most tested and commonly used P2Y12 inhibitor monotherapy following percutaneous coronary intervention. The purpose of this study is to conduct a head-to-head comparison on the pharmacodynamic efficacy of ticagrelor-based and prasugrel-based single antiplatelet therapy. To determine if the PD profiles of ticagrelor- and prasugrel-based SAPT are comparable, we aim to conduct a non-inferiority study between the two strategies.

Key facts

Study ID

NCT06691191

Run by

University of Florida

People needed

48

Starts

2025-01-08

Expected to finish

2026-12-31

Last updated by the study team

2026-02-05

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients on DAPT with aspirin plus prasugrel 10 mg or ticagrelor 90 mg bid as per standard of care at least 90 days after PCI.
• Age between 18 and 75 years old
• Able to provide written informed consent

You may not qualify if…

• Prior history of stent thrombosis
• PCI within 90 days.
• History of stroke/TIA
• Age > 75 years old
• Weight < 60 kg
• History of intracranial hemorrhage
• On treatment with any oral anticoagulant or chronic low-molecular-weight heparin (at venous thrombosis treatment, not for prophylaxis)
• Patients with known coagulation disorders
• Known severe hepatic impairment
• Hypersensitivity to prasugrel or ticagrelor
• Pregnant and breastfeeding persons [persons of childbearing age must use reliable birth control (i.e., oral contraceptives) while participating in the study]. If the potential subject is a person of childbearing potential, a pregnancy test will be done. If the subject is pregnant, participation in this study will end.

Where it is running

• University of Florida Jacksonville — Jacksonville, Florida, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.